Update on commencement of dealings

RNS Number : 5871J

Evocutis PLC

08 August 2012

 



Press Release

8 August 2012

Evocutis plc

("Evocutis" or "the Company")

Update on commencement of dealings

Evocutis plc (AIM: EVO), the company focused on advanced laboratory and clinical evaluations

of skincare products for the health and cosmetic markets, today updates the market on the announcement of 1 August in which it was announced that it had issued a total of 595,238 new ordinary shares of 1 pence each in the Company ("New Ordinary Shares") at a price of 1.12 pence per share.

As previously announced, application has been made for these New Ordinary Shares to be admitted to trading on AIM.  The shares rank pari passu with the existing issued shares of the Company and dealings are now expected to commence on 9 August 2012.  Following the issue of these new shares, the Company has a total of 173,774,928 ordinary shares of 1 pence each in issue.

- Ends -

For further information, please contact:

Evocutis plc
Darren Bamforth, Finance Director	[phone]
	www.evocutis.com

Zeus Capital Limited
Andrew Jones	Tel: [phone]
Nick Cowles	www.zeuscapital.co.uk

Notes to editors

About Evocutis plc

With a rich portfolio of new product opportunities, Evocutis offers antimicrobial and dermatological expertise to the cosmetic, consumer healthcare and pharmaceutical industries.  Being uniquely able to combine research for laboratory testing, advanced skin models and clinical testing, Evocutis offers a complete service for the development of skin care products and ingredients. Through research and testing we enable our clients to advance the discovery of skin care products that actually work.

Offering high quality contract research services, Evocutis specialises in Human Skin Microbiology, tissue culture systems and Human Volunteer and Clinical Dermatology Research. Unique characteristics of its colonised full thickness model of human skin (LabSkin™) allow rapid, cost effective screening of, for example, anti-ageing, anti-inflammatory and antimicrobial ingredients and products for use on skin. Additionally, the clinical, human volunteer testing facility that is housed on-site provides rapid, bespoke evaluation of dermatological products.

When it comes to advanced laboratory and clinical evaluations of skincare products for the health and cosmetic markets, the Evocutis focus is simple: intelligent and specialised R&D input. 

For further information, please see www.evocutis.com

About LabSkin™

LabSkin™ is an animal-replacement technology, that emulates living skin tissue and is a high value research and product testing tool for the cosmetic and healthcare industries. It is a full thickness human skin model, comprised of both dermal and epidermal layers, and is produced exclusively and reproducibly on site at Evocutis from primary human cells (keratinocytes & fibroblasts). The model exhibits a fully differentiated epidermal layer, which provides a completely dry surface for tailored testing requirements.

LabSkin™ is highly versatile, and alongside its antimicrobial model, Evocutis is developing models to test anti-ageing and moisturising products. The antimicrobial LabSkin™ model allows testing using pathogenic microorganisms which would not be possible in human clinical studies. In addition, methods have been developed to allow LabSkin™ to be inoculated with skin washings taken directly from human skin, thus providing a step-change in the quality of data possible from a laboratory model.  By benchmarking activity against best-in-class products, the activity of new ingredients and formulations can be assessed for several antimicrobial endpoints, including immediate kill, rate of kill and residual activity. 

Recent research indicates that our natural microflora is an integral part of our skin and makes a significant contribution to skin health.  LabSkin™ provides a unique living skin surface which is validated for microbial applications and can simultaneously provide information on irritation, penetration, barrier function and skin structure.

 

END

 

 

MSCBBGDIXDGBGDI